The role of alpelisib in the treatment of PIK3CA - a mutated breast cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Hormone-dependent (ER/PR-positive), human epidermal growth factor 2 receptor-negative (HR+/HER2 negative) breast cancer (BC) accounts for more than 70% of all BC cases. Significant progress in the treatment of HR+/HER2-negative metastatic breast cancer (mBC) has been made, in particular, more adapted and targeted treatments have been developed. Recently, a better understanding of the role of the PI3K/AKT/mTOR signaling pathway in BC has led to the development of PI3K inhibitors that have proven effective in the treatment of HR+/HER2-negative mBC. The role of the PI3K/AKT/mTOR pathogenetic pathway in BC and treatment methods aimed at PI3K inhibition were studied. The development of the PI3K inhibitor alpelisib, indications for its use in HR+/HER2-negative mBC has been completed, safety and tolerability as well as the future direction of this therapy in the treatment of breast cancer are being discussed.

Full Text

Restricted Access

About the authors

V. F Semiglazov

N.N. Petrov Research Institute of Oncology

St. Petersburg, Russia

P. V Krivorotko

N.N. Petrov Research Institute of Oncology

St. Petersburg, Russia

A. V Komyakhov

N.N. Petrov Research Institute of Oncology

St. Petersburg, Russia

T. Yu Semiglazova

N.N. Petrov Research Institute of Oncology

St. Petersburg, Russia

L. P Gigolaeva

N.N. Petrov Research Institute of Oncology

St. Petersburg, Russia

T. T Tabagua

N.N. Petrov Research Institute of Oncology

St. Petersburg, Russia

Maria D. Kazantseva

N.N. Petrov Research Institute of Oncology

Email: sokolmd_1998@mail.ru
St. Petersburg, Russia

A. P Tergoeva

N.N. Petrov Research Institute of Oncology

St. Petersburg, Russia

D. G Ulrikh

N.N. Petrov Research Institute of Oncology

St. Petersburg, Russia

M. V Chervyak

N.N. Petrov Research Institute of Oncology

St. Petersburg, Russia

V. V Klimenko

N.N. Petrov Research Institute of Oncology

St. Petersburg, Russia

N. S Amirov

N.N. Petrov Research Institute of Oncology

St. Petersburg, Russia

E. K Zhiltsova

N.N. Petrov Research Institute of Oncology

St. Petersburg, Russia

V. V Semiglazov

N.N. Petrov Research Institute of Oncology

St. Petersburg, Russia

References

  1. Мерабишвили В.М. Состояние онкологической помощи в России: рак молочной железы среди женского населения. Заболеваемость смертность, достоверность учета, детальная локализационная и гистологическая структура. (Популяционное исследование на уровне федерального округа). Вопросы онкологии. 2022;68(3):286-93
  2. Мерабишвили В.М. Состояние онкологической помощи в России: рак молочной железы среди женского населения. Погодичная летальность, медиана выживаемости, выживаемость больных. (Популяционное исследование на уровне федерального округа). Вопросы онкологии. 2022;68(3):294-301
  3. Переводчикова Н.И., Стенина М.Б. Лекарственная терапия рака молочной железы. М.: Практика, 2014. 284 с
  4. Поддубная И.В., Глигоров Д., Жукова Л.Г. и др. Виртуальный форум по вопросам диагностики и лечени метастатического рака молочной железы с мутацией PiK3CA. Современная онкология. 2020;22(4):47-55.
  5. Andre F., Ciruelos E., Rubovszky G., et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929-40. Doi: 10.1056/ NEJMoa1813904.
  6. Howlader N., Altekruse S.F., Li C.I., et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014;106:dju055.
  7. Cardoso F., Paluch-Shimon S., Senkus E., et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623-49. Doi: 10.1016/j. annonc.2020.09.010.
  8. Rugo H.S., Rumble R.B., Macrae E., et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016;34:3069-103. doi: 10.1200/JCO.2016.67.1487.
  9. Miller T.W., Balko J.M., Arteaga C.L. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29:4452-61. Doi: 10.1200/ JCO.2010.34.4879.
  10. Moynahan M.E., Chen D., He W., et al. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HRfa, HER2- advanced breast cancer: results from BOLERO-2. Br J Cancer. 2017;116:726-30. doi: 10.1038/bjc.2017.25.
  11. Cancer Genome Atlas Network.Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61. Doi: 10.1038/ nature11412.
  12. Соколова Т.Н., Соловьева Т.И., Алексахи-на С.Н. и др. Клинико-морфологические особенности опухолей молочной железы с мутациями PIK3CA у российских больных: наблюдательное исследование. Современная Онкология. 2022;24(1):12-23
  13. Rajadurai P., Semiglazova T., Hegmane A., et al. PIK3CA Registry: A Noninterventional, Descriptive, Retrospective Cohort Study of PIK3CA Mutations in Patients With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer (ABC). Presented at SABCS 2021. P5-13-25. URL: https://www.medicalcongress.novartisoncology.com/SABCS/BC/pdf/poster_slides/Rajadurai_Posterslides_P5-13-25.pdf (access date 28.09.2022).
  14. FDA highlights of prescribing information: alpelisib. Version 5. 2019. Available from : https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf (Accessed April 3, 2020).
  15. Juric D, Janku F., Rodon J., et al. Alpelisib plus fulvestrant in PIK3CAaltered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial. JAMA Oncol. 2019;5:e184475. Doi: 10.1001/ jamaoncol.2018.4475.
  16. Fritsch C, Huang A., Chatenay-Rivauday C., et al. Characterization of the novel and specific PI3Ka inhibitor NVP-BYL719 and development of the patient stratification strategy for clinicaltrials. Mol Cancer Ther. 2014;13:1117-29. doi: 10.1158/1535-7163.MCT-13-0865.
  17. Fritsch C, Pfister E., Ebel N., et al. Determination of the PI3Ka selective inhibitor alpelisib mechanism of action and efficacy in ERfa/PIK3CA mutant breast cancer preclinical models. Paper presented at: American Association for Cancer Research 2018 Annual Meeting; 14-18 April 2018; Chicago, IL. Abstract 3934.
  18. Juric D., Ciruelos E.M., Rubovszky G., et al. Alpelisib (ALP) fa fulvestrant (FUL) for advanced breast cancer (ABC): phase 3 SOLAR-1 trial results. Paper presented at: San Antonio Breast Cancer Symposium; 4-8 December 2018; San Antonio, TX. Abstract GS3-08.
  19. Brandao M., Maurer C., Ziegelmann PK., et al. Endocrine therapybased treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network metaanalysis. ESMO Open. 2020;5:e000842. doi: 10.1136/esmoopen-2020-000842.
  20. Razavi P, Dickler M.N., Shah P.D., et al. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer. 2020;1(4):382-393. doi: 10.1038/s43018-020-0047-1.
  21. Vasan N., Razavi P., Johnson J.L., et al. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Ka inhibitors. Science. 2019;366(6466):714-23. Doi: 10.1126/ science.aaw9032.
  22. Rugo H.S., Lerebours F., Ciruelos E. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22:489-98. doi: 10.1016/S1470-2045(21)00034-6.
  23. Di Leo A., Johnston S., Lee K.S., et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:87-100. Doi: 10.1016/ S1470-2045(17)30688-5.
  24. Cristofanilli M., Turner N.C., Bondarenko I., et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormonereceptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425-39. Doi: 10.1016/ S1470-2045(15)00613-0.
  25. Baselga J., Im S.A., Iwata H., et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptorpositive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:904-16. doi: 10.1016/S1470- 2045(17)30376-5.
  26. Seidman A.D., Bordeleau L., Fehrenbacher L., et al. National Cancer Institute Breast Cancer Steering Committee Working Group report on meaningful and appropriate end points for clinical trials in metastatic breast cancer. J Clin Oncol. 2018;36:3259-68. Doi: 10.1200/ JCO.18.00242.
  27. Rugo H.S., Lerebours F., Ciruelos E. Alpelisib fa fulvestrant in patients with PIK3CA-Mutated hormone-receptor positive (HRfa), human epidermal growth factor receptor-2-negative (HER2e) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) fa aromatase inhibitor (AI): BYLieve study results. Paper presented at: Virtual American Society of Clinical Oncology 2020 Annual Meeting; 29-31 May 2020. Abstract 1006.
  28. Rugo H.S., Andre F., Yamashita T., et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020;31:1001-10. Doi: 10.1016/j. annonc.2020.05.001.
  29. Mayer I.A., Rugo H.S., Loibl S., et al. Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer from SOLAR-1. Paper presented at: American Society of Clinical Oncology 2019 Annual Meeting; 31 May-4 June; Chicago, IL. Abstract 1039.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies